Baird downgraded Medpace (MEDP) to Neutral from Outperform with a price target of $349, down from $413. The firm says it is hard to see Medpace getting much multiple expansion with low net new business and revenue growth potentially declining in 2025. The company’s cancellation issues are likely transitory, however, and should see strong reacceleration into 2026, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDP:
- Closing Bell Movers: Medpace down 11% after cutting FY24 revenue guide
- Medpace reports Q3 EPS $3.01, consensus $2.78
- Medpace raises FY24 EPS view to $11.71-$12.09 from $11.24-$11.93
- Options Volatility and Implied Earnings Moves Today, October 21, 2024
- Medpace Holdings Inc (MEDP) Q3 Earnings Cheat Sheet